- Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 TranscriptFeb 25, 2024
- Celldex Therapeutics Inc Conference Call & Webcast TranscriptNov 06, 2023
- Celldex Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Celldex Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Celldex Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria TranscriptFeb 26, 2023
- Celldex Therapeutics Inc Barzolvolimab Global Urticaria Forum 2022 Data Presentations and Program Update Call TranscriptDec 06, 2022
- Celldex Therapeutics Inc Corporate Call - Barzolvolimab Interim Phase 1b Multiple Ascending Dose Chronic Spontaneous Urticaria Study Results EAACI 2022 TranscriptJun 30, 2022
- Q4 2021 Celldex Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$29.9 (-0.83%)Earnings
- Celldex Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) TranscriptFeb 16, 2022
- Celldex Therapeutics Inc to Discuss the CDX-0159 Phase 1b Study Results in Cold Urticaria and Symptomatic Dermographism Late Breaking Presentation at EAACI 2021 - Conference Call TranscriptJul 12, 2021
- Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update TranscriptMar 29, 2021
- Q2 2020 Celldex Therapeutics Inc Earnings Call TranscriptAug 06, 2020$11.71 (+1.39%)Earnings
- Celldex Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Q2 2019 Celldex Therapeutics Inc Earnings Call TranscriptAug 07, 2019$2.16 (+3.85%)Earnings
- Q4 2018 Celldex Therapeutics Inc Earnings Call TranscriptMar 07, 2019$4.6 (-1.71%)Earnings
Celldex Therapeutics Inc Conference Call & Webcast Transcript
Good morning. My name is Krista, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Celldex Conference Call and Webcast. (Operator Instructions)
I will now turn the conference over to Sarah Cavanaugh. You may begin your conference.
Good morning, and thank you for joining us to discuss clinical results from our Barzolvolimab program in Chronic Spontaneous Urticaria and Prurigo Nodularis this morning.
On our call, I have Anthony Marucci, Co-Founder, President and CEO; Dr. Diane Young, Senior Vice President and Chief Medical Officer; Dr. Tibor Keler, Co-Founder, Executive Vice President and Chief Scientific Officer; Dr. Margo Heath-Chiozzi, Senior Vice President of Regulatory Affairs; and Dr. Diego Alvarado, Executive Director of Research and Research Lead on the program.
Before we begin our discussion, I would like to direct your attention to Slide 2 with respect to important information regarding
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)